• Artelo Biosciences presented new human metabolite profiling results for pain candidate ART26.12 at a London DMPK and medicinal chemistry conference.
• Data came from plasma samples in a recently completed single-ascending-dose study in healthy volunteers.
• The profile indicated limited metabolism, with most circulating drug-related material remaining as the parent compound.
• No human-specific metabolites were seen, supporting a low-risk safety assessment for metabolites already qualified in toxicology testing.
• Artelo framed the findings as reducing development complexity for ART26.12 as it advances in clinical development for pain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100738PRIMZONEFULLFEED9734380) on June 10, 2026, and is solely responsible for the information contained therein.